| Abstract | The treatment of cancer by targeting angiogenesis and depriving growing tumors of their blood supply has been recognized as an interesting therapeutic possibility for several decades. A multitude of development programs investigating both low-molecular-weight substances and biologicals, in particular monoclonal antibodies (mAbs), have been instigated. The generation of human or human-like mAbs has led to the recent development of therapeutic antibodies that are potentially highly beneficial in the treatment of cancer. Avastin, which binds to the pro-angiogenic factor vascular endothelial growth factor, is one of the most promising of these antibodies, and has proved beneficial in the treatment of colorectal, lung and breast cancer, with a potential to be used also in other types of cancer. However, as angiogenesis is a complex process controlled by both pro-angiogenic as well as anti-angiogenic factors, several research and development programs targeting different pro-angiogenic factors, receptors and antigens that are selectively expressed on cells in newly formed blood vessels are under way. At BioInvent International AB, research is focused on angiomotin, a newly discovered receptor for the anti-angiogenic factor angiostatin, and on the pro-angiogenic factor placenta growth factor. |
| Authors | Patrik Andreasson, Roland Carlsson
(Affiliation: BioInvent International AB, Sölvegaten 41, SE-223 70 Lund, Sweden.)
|
| Journal | IDrugs : the investigational drugs journal
(IDrugs)
Vol. 8
Issue 9
Pg. 730-3
(Sep 2005)
ISSN: 1369-7056 England |
| PMID | 16118694
(Publication Type: Journal Article)
|
| Chemical References |
- AMOT protein, human
- Antibodies, Monoclonal
- Carrier Proteins
- Intercellular Signaling Peptides and Proteins
- Membrane Proteins
- PIGF protein, human
- Proteins
- vitaxin
|
| Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Carrier Proteins
(antagonists & inhibitors)
- Humans
- Intercellular Signaling Peptides and Proteins
- Membrane Proteins
- Neoplasms
(blood supply, therapy)
- Neovascularization, Pathologic
(therapy)
- Proteins
(antagonists & inhibitors)
|
